biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
Company profile
Ticker
BMEA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BMEA stock data
Latest filings (excl ownership)
8-K
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
1 Apr 24
8-K
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
7 Mar 24
8-K
Other Events
10 Jan 24
S-8
Registration of securities for employees
5 Jan 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
8-K
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
30 Oct 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
8-K
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
31 Jul 23
Latest ownership filings
SC 13G
STATE STREET CORP
10 Apr 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Erdtmann Rainer M
12 Feb 24
SC 13G/A
Butler Thomas Andrew
12 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
Laurion Capital Management LP
8 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Thomas Andrew Butler
18 Jan 24
4
Rainer M Erdtmann
18 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 199.46 mm | 199.46 mm | 199.46 mm | 199.46 mm | 199.46 mm | 199.46 mm |
Cash burn (monthly) | 7.93 mm | (no burn) | 10.37 mm | 9.59 mm | 7.97 mm | 7.83 mm |
Cash used (since last report) | 54.02 mm | n/a | 70.63 mm | 65.30 mm | 54.24 mm | 53.31 mm |
Cash remaining | 145.44 mm | n/a | 128.83 mm | 134.16 mm | 145.22 mm | 146.15 mm |
Runway (months of cash) | 18.3 | n/a | 12.4 | 14.0 | 18.2 | 18.7 |
Institutional ownership, Q3 2023
96.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 90 |
Opened positions | 12 |
Closed positions | 24 |
Increased positions | 35 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 412.04 bn |
Total shares | 34.66 mm |
Total puts | 304.20 k |
Total calls | 232.00 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 5.34 mm | $73.54 bn |
Cormorant Asset Management | 3.57 mm | $49.14 bn |
Cormorant Global Healthcare Master Fund | 3.57 mm | $114.09 mm |
JHG Janus Henderson | 2.98 mm | $40.96 bn |
Laurion Capital Management | 2.61 mm | $35.96 bn |
STT State Street | 2.30 mm | $31.63 bn |
Baker Bros. Advisors | 2.11 mm | $29.02 bn |
BLK Blackrock | 2.07 mm | $28.46 bn |
Vanguard | 1.34 mm | $18.43 bn |
Driehaus Capital Management | 912.87 k | $12.56 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jan 24 | Franco Valle | Stock Option Common Stock | Grant | Acquire A | No | No | 14.44 | 145,245 | 2.10 mm | 145,245 |
17 Jan 24 | Thomas Andrew Butler | Stock Option Common Stock | Grant | Acquire A | No | No | 14.44 | 407,502 | 5.88 mm | 407,502 |
17 Jan 24 | Rainer M Erdtmann | Stock Option Common Stock | Grant | Acquire A | No | No | 14.44 | 135,700 | 1.96 mm | 135,700 |
17 Jan 24 | Juan Pablo Frias | Stock Option Common Stock | Grant | Acquire A | No | No | 14.44 | 111,090 | 1.60 mm | 111,090 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Dispose G | No | No | 0 | 12,000 | 0.00 | 713,027 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Acquire G | Yes | No | 0 | 3,000 | 0.00 | 10,000 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Dispose G | No | No | 0 | 3,000 | 0.00 | 725,027 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Acquire G | Yes | No | 0 | 3,000 | 0.00 | 10,000 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Dispose G | No | No | 0 | 3,000 | 0.00 | 728,027 |
29 Dec 23 | Rainer M Erdtmann | Common Stock | Gift | Acquire G | Yes | No | 0 | 3,000 | 0.00 | 9,400 |
News
Oppenheimer Maintains Outperform on Biomea Fusion, Maintains $70 Price Target
3 Apr 24
JP Morgan Downgrades Biomea Fusion to Neutral, Lowers Price Target to $14
2 Apr 24
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
1 Apr 24
Truist Securities Reiterates Buy on Biomea Fusion, Maintains $55 Price Target
1 Apr 24
Biomea Fusion Q4 EPS $(0.98) Misses $(0.85) Estimate
1 Apr 24
Press releases
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
1 Apr 24
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
6 Mar 24
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24